Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1

被引：50

作者：

Wallis, Carole L. ^{[1
]}

Papathanasopoulos, Maria A.

Lakhi, Shabir ^{[2
]}

Karita, Etienne ^{[3
]}

Kamali, Anatoli

Kaleebu, Pontiano

Sanders, Eduard ^{[4
]}

Anzala, Omu ^{[5
]}

Bekker, Linda-Gail ^{[6
]}

Stevens, Gwynn ^{[7
]}

de Wit, Tobias F. Rinke ^{[8
]}

Stevens, Wendy ^{[9
]}

机构：

[1] Univ Witwatersrand, Wits Med Sch, Dept Mol Med & Hematol, ZA-2193 Parktown, South Africa

[2] ZEHRP, Lusaka, Zambia

[3] PSF, Kigali, Rwanda

[4] KEMRI, CGMRC, Kilifi, Kenya

[5] Kenya AIDS Vaccine Initiat, Nairobi, Kenya

[6] Desmond Tutu HIV Fdn, Cape Town, South Africa

[7] Internation AIDS Vaccine Initiat Johannesburg, Johannesburg, South Africa

[8] Univ Amsterdam, Med Acad, CPCD,AIGHD, Dept Internal Med,Ctr Infect & Immun CINIMA, NL-1012 WX Amsterdam, Netherlands

[9] NHLS, Johannesburg, South Africa

来源：

JOURNAL OF VIROLOGICAL METHODS | 2010年 / 163卷 / 02期

基金：

英国医学研究理事会;

关键词：

HIV-1 subtype C; Antiretroviral drug resistance; Mutation profile; Affordable; INFECTION; SYSTEM;

D O I：

10.1016/j.jviromet.2009.11.011

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

The introduction of antiretroviral (ARV) therapy in resource-poor settings is effective in suppressing HIV-1 replication and prolonging life of infected individuals. This has led to a demand for affordable HIV-1 drug resistance assays, since treatment failure due to development of drug resistance is common. This study developed and evaluated an affordable "in-house" genotyping assay to monitor HIV-1 drug resistance in Africa, particularly South Africa. An "in-house" assay using automated RNA extraction, and subtype C specific PCR and sequencing primers was developed and successfully evaluated 396 patient samples (viral load ranges 1000-1.6 million RNA copies/ml). The "in-house" assay was validated by comparing sequence data and drug resistance profiles from 90 patient and 10 external quality control samples to data from the ViroSeq (TM) HIV-1 Genotyping kit. The "in-house" assay was more efficient, amplifying all 100 samples, compared to 91 samples using Viroseq. The "in house" sequences were 99.2% homologous to the ViroSeq sequences, and identical drug resistance mutation profiles were observed in 96 samples. Furthermore, the "in-house" assay genotyped 260 of 295 samples from seven African sites, where 47% were non-subtype C. Overall, the newly validated "in-house" drug resistance assay is suited for use in Africa as it overcomes the obstacle of subtype diversity. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：505 / 508

页数：4

共 11 条

[1] The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world [J].

Bennett, Diane E. .

CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) :607-614

[2]

ENGELBRECHT S, 2007, SENSITIVE IN HOUSE R, P528

[3] Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-base analysis of diverse human immunodeficiency virus type 1 strains [J].

Eshleman, SH ;

Hackett, J ;

Swanson, P ;

Cunningham, SP ;

Drews, B ;

Brennan, C ;

Devare, SG ;

Zekeng, L ;

Kaptué, L ;

Marlowe, N .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (06) :2711-2717

[4] Immunopathogenic mechanisms of HIV infection [J].

Fauci, AS ;

Pantaleo, G ;

Stanley, S ;

Weissman, D .

ANNALS OF INTERNAL MEDICINE, 1996, 124 (07) :654-663

[5] Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel [J].

Hirsch, Martin S. ;

Guenthard, Huldrych F. ;

Schapiro, Jonathan M. ;

Brun-Vezinet, Francoise ;

Clotet, Bonaventura ;

Hammer, Scott M. ;

Johnson, Victoria A. ;

Kuritzkes, Daniel R. ;

Mellors, John W. ;

Pillay, Deenan ;

Yeni, Patrick G. ;

Jacobsen, Donna M. ;

Richman, Douglas D. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) :266-285

[6]

*INT TREATM PREP C, 2007, MISS TARG NUMB 4 TIM

[7] Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system [J].

Kuritzkes, DR ;

Grant, RM ;

Feorino, P ;

Griswold, M ;

Hoover, M ;

Young, R ;

Day, S ;

Lloyd, RM ;

Reid, C ;

Morgan, GF ;

Winslow, DL .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1594-1599

[8]

LEE S, 1999, INT C ANT AG CHEM, V39, P462

[9]

LOUBSHER S, 2004, ANTIVIR THER, V9, pS145

[10] Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa [J].

Marconi, Vincent C. ;

Sunpath, Henry ;

Lu, Zhigang ;

Gordon, Michelle ;

Koranteng-Apeagyei, Kofi ;

Hampton, Jane ;

Carpenter, Steve ;

Giddy, Janet ;

Ross, Douglas ;

Holst, Helga ;

Losina, Elena ;

Walker, Bruce D. ;

Kuritzkes, Daniel R. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) :1589-1597

← 1 2 →